Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373800 | 1.00 | L3MBTL1 (0.45) | L3MBTL1MMP8MCHR1RORCTACR1 | |
| SCHEMBL2373787 | 0.90 | GAA (0.52) | L3MBTL1RORCSMN1; SMN2POLBGFER | |
| SCHEMBL2373778 | 0.90 | GAA (0.52) | L3MBTL1RORCSMN1; SMN2POLBGFER | |
| SCHEMBL2373502 | 0.82 | GPR142 (0.44) | MCHR1TACR1OPRD1 | |
| SCHEMBL2373494 | 0.82 | GPR142 (0.44) | MCHR1TACR1OPRD1 | |
| SCHEMBL2375944 | 0.80 | MCHR1 (0.45) | MCHR1TACR1OPRD1MEN1KMT2A | |
| SCHEMBL2375951 | 0.80 | MCHR1 (0.45) | MCHR1TACR1OPRD1MEN1KMT2A | |
| SCHEMBL2374734 | 0.80 | DPP4 (0.46) | MCHR1TACR1SMN1; SMN2OPRD1 | |
| SCHEMBL2374722 | 0.80 | DPP4 (0.46) | MCHR1TACR1SMN1; SMN2OPRD1 | |
| SCHEMBL2375734 | 0.79 | POLB (0.57) | L3MBTL1SMN1; SMN2POLBGFERMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | L3MBTL1 3413/4885MMP8 2785/4885MCHR1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.